<DOC>
	<DOCNO>NCT02180789</DOCNO>
	<brief_summary>This open-label , single-arm , prospective interventional study assess tolerability efficacy Harnalidge® OCAS® 0.4 mg Taiwan patient unsatisfied tamsulosin 0.2 mg treatment low urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>A Study Evaluate Tolerability Efficacy Tamsulosin 0.4mg OCAS Formulation Patients Who Are Unsatisfied With Treatment Tamsulosin 0.2mg Conventional Formulation</brief_title>
	<detailed_description>After obtain informed consent , subject meet inclusion criterion violate exclusion criterion enrol receive Harnalidge® OCAS® 0.4 mg treatment . The interventional period study three month first date enrollment patient discontinue treatment Harnalidge® OCAS® . All subject instruct contact site patient 's partner become pregnant within 90 day discontinuation dosing , investigator report information sponsor SAE .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Diagnosed LUTS associated BPH Currently take oral tamsulosin 0.2 mg least 4 week Unsatisfied treatment tamsulosin 0.2 mg The definition 'unsatisfaction ' base patient 's satisfaction . Investigator ask patient one question `` Are satisfied current treatment ? '' prior study enrollment IPSSQOL score ≧3 point baseline Subjects underwent prostatectomy period one year prior study Subjects neurogenic bladder dysfunction , bladder neck sclerosis , urethral stricture , prostatic cancer , cystolithiasis , severe vesical diverticulum , urinary tract infection Subjects complication may cause void dysfunction Subjects severe hepatic dysfunction , severe renal dysfunction , severe cardiovascular disorder , orthostatic hypotension , senile dementia Subjects clinically significant condition , opinion investigator make patient unsuitable trial Subjects currently participate investigational drug study participate study investigational drug within 3 month prior study</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>tamsulosin ,</keyword>
	<keyword>benign prostatic hyperplasia ,</keyword>
	<keyword>α1-adrenoceptor antagonist</keyword>
</DOC>